Tyler Zeronda
Chief Financial OfficerMr. Tyler Zeronda, CPA, is Chief Financial Officer of Yarrow Bioscience, Inc since July 27, 2026. Mr. Zeronda served as Chief Financial Officer at VYNE Therapeutics Inc. since March 14, 2022 and served as its Interim Chief Financial Officer until March 14, 2022. Mr. Zeronda was Treasurer at VYNE Therapeutics Inc. since June 18, 2021 and was its Vice President of Finance until June 18, 2021. Mr. Zeronda joined Foamix in April 2019 and has been responsible for all finance activities related to the commercial operations, financial planning, treasury, risk management and supply chain matters of the Company. From April 2013 until April 2019, Mr. Zeronda held positions of increasing responsibility in finance at Aerie Pharmaceuticals Inc. (“Aerie”), a Nasdaq listed company, culminating in his role as Director of Finance. While at Aerie, Mr. Zeronda helped lead his department’s transition from that of a development-stage entity to a fully integrated commercial finance organization supporting the launch of multiple drugs. Prior to joining Aerie, Mr. Zeronda was employed at Ernst & Young, LLP where he focused on assurance services in the healthcare industry. Mr. Zeronda received his Master of Science in accounting from the University of Virginia, holds a Bachelor of Arts in economics and business from Lafayette College and is a licensed CPA.
Positions
- Company NameYarrow Bioscience, Inc.Stock CodeYARWPositionChief Financial Officer
